Nerve-Sparing Cryoablation for the Treatment of Primary Prostate Cancer: the Preliminary Report
Abstract Background: To present a pilot study of nerve-sparing cryoablation for the treatment of primary prostate cancer. Materials and Methods: Between 2008 and 2011, 9 patients underwent nerve-sparing cryoablation (unilateral 5, bilateral 4 patients). One neurovascular bundle (NVB) was spared on t...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kosin University College of Medicine
2014-12-01
|
| Series: | Kosin Medical Journal |
| Subjects: | |
| Online Access: | http://www.kosinmedj.org/upload/pdf/ksmc029-02-06.pdf |
| _version_ | 1811256368965877760 |
|---|---|
| author | Seong Choi |
| author_facet | Seong Choi |
| author_sort | Seong Choi |
| collection | DOAJ |
| description | Abstract Background: To present a pilot study of nerve-sparing cryoablation for the treatment of primary prostate cancer. Materials and Methods: Between 2008 and 2011, 9 patients underwent nerve-sparing cryoablation (unilateral 5, bilateral 4 patients). One neurovascular bundle (NVB) was spared on the side opposite the positive biopsy, and two NVBs were spared when indicated and possible. Just before the start of freezing, a 22-gauge spinal needle was placed into Denonvilliers fascia using a transperineal route, and normal saline was injected to separate the rectum from the prostate. The prostate-specific antigen (PSA) level was sampled every 3 months for the first 2 years and then every 6 months thereafter. Patients were considered to have a stable PSA if they had two consecutive PSA measurements without a rise. Results: The follow-up was 4ᄋ-months (19-66 months). All patients had stable PSA levels at last follow-up. Potency (defined as an erection sufficient to complete intercourse to the satisfaction of the patient) was maintained in 4 of 9 patients, 5 were potent with phosphodiesterase 5 inhibitors or intracavernosal injection. Conclusions: Nerve-sparing cryoablation, in which one or two neurovascular bundle is spared, showed the possibility of preserving potency in most patients without compromising cancer control. These preliminary results warrant further study. |
| first_indexed | 2024-04-12T17:39:07Z |
| format | Article |
| id | doaj.art-f817ed0186934797b6ad7b2779c498b0 |
| institution | Directory Open Access Journal |
| issn | 2005-9531 2586-7024 |
| language | English |
| last_indexed | 2024-04-12T17:39:07Z |
| publishDate | 2014-12-01 |
| publisher | Kosin University College of Medicine |
| record_format | Article |
| series | Kosin Medical Journal |
| spelling | doaj.art-f817ed0186934797b6ad7b2779c498b02022-12-22T03:22:51ZengKosin University College of MedicineKosin Medical Journal2005-95312586-70242014-12-0129213514010.7180/kmj.2014.29.2.135139Nerve-Sparing Cryoablation for the Treatment of Primary Prostate Cancer: the Preliminary ReportSeong Choi0Deparment of Urology, College of Medicine, Kosin University, Busan, KoreaAbstract Background: To present a pilot study of nerve-sparing cryoablation for the treatment of primary prostate cancer. Materials and Methods: Between 2008 and 2011, 9 patients underwent nerve-sparing cryoablation (unilateral 5, bilateral 4 patients). One neurovascular bundle (NVB) was spared on the side opposite the positive biopsy, and two NVBs were spared when indicated and possible. Just before the start of freezing, a 22-gauge spinal needle was placed into Denonvilliers fascia using a transperineal route, and normal saline was injected to separate the rectum from the prostate. The prostate-specific antigen (PSA) level was sampled every 3 months for the first 2 years and then every 6 months thereafter. Patients were considered to have a stable PSA if they had two consecutive PSA measurements without a rise. Results: The follow-up was 4ᄋ-months (19-66 months). All patients had stable PSA levels at last follow-up. Potency (defined as an erection sufficient to complete intercourse to the satisfaction of the patient) was maintained in 4 of 9 patients, 5 were potent with phosphodiesterase 5 inhibitors or intracavernosal injection. Conclusions: Nerve-sparing cryoablation, in which one or two neurovascular bundle is spared, showed the possibility of preserving potency in most patients without compromising cancer control. These preliminary results warrant further study.http://www.kosinmedj.org/upload/pdf/ksmc029-02-06.pdfcancercryoablationpotencyprostate |
| spellingShingle | Seong Choi Nerve-Sparing Cryoablation for the Treatment of Primary Prostate Cancer: the Preliminary Report Kosin Medical Journal cancer cryoablation potency prostate |
| title | Nerve-Sparing Cryoablation for the Treatment of Primary Prostate Cancer: the Preliminary Report |
| title_full | Nerve-Sparing Cryoablation for the Treatment of Primary Prostate Cancer: the Preliminary Report |
| title_fullStr | Nerve-Sparing Cryoablation for the Treatment of Primary Prostate Cancer: the Preliminary Report |
| title_full_unstemmed | Nerve-Sparing Cryoablation for the Treatment of Primary Prostate Cancer: the Preliminary Report |
| title_short | Nerve-Sparing Cryoablation for the Treatment of Primary Prostate Cancer: the Preliminary Report |
| title_sort | nerve sparing cryoablation for the treatment of primary prostate cancer the preliminary report |
| topic | cancer cryoablation potency prostate |
| url | http://www.kosinmedj.org/upload/pdf/ksmc029-02-06.pdf |
| work_keys_str_mv | AT seongchoi nervesparingcryoablationforthetreatmentofprimaryprostatecancerthepreliminaryreport |